TrialHepatology (Baltimore, Md.)2017

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Yingjie Bian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.